NEW YORK (GenomeWeb) – Intrexon has entered into a definitive agreement to buy bovine genetics firm Trans Ova Genetics for up to $110 million. Shareholders will receive $60 million in upfront cash, $30 million in Intrexon stock, and up to $20 million in deferred payments. Trans Ova will become a wholly owned subsidiary of Intrexon upon completion of the transaction, which is expected in the third quarter, and will be led by David Faber, currently Trans Ova's president, and his management team.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.